Glucotrack executed multiple financing agreements to strengthen liquidity. The company added $3.5 million of senior secured convertible notes in a Bridge Follow-On with associated warrants, featuring an 8% coupon and a 22% original issue discount, with conversion and exercisability subject to stock…
Glucotrack (NASDAQ: GCTK) today announced the continued expansion of the ai² Futures Lab™ operated through its wholly owned subsidiary, Lōkahi Therapeutics™ Inc. During its first year, the ai² Futures Lab™ identified more than 45 therapeutic opportunities on a budget of approximately $33,000 and ad…
Lōkahi Therapeutics™ Inc., a wholly owned subsidiary of Glucotrack, Inc. (NASDAQ: GCTK), today announced progress in its LT-100 development strategy focused on evaluating whether a historical administration approach requiring up to 15 intradermal (ID) injections per treatment visit can be simplifie…
GlucoTrack entered into an Exchange Agreement with an investor to create a $900,000 partitioned promissory note from an existing note and permit exchanges of the new note into common stock. Exchange shares will be issued at the lower of the prior day’s Nasdaq Official Closing Price or the five-day…
Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset sourcing, development, and advancement platformRUTHERFORD, N.J. and LA JOLLA, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Glucotrack…
Glucotrack closed a stock-for-stock merger with Lokahi Therapeutics, making Lokahi a wholly owned subsidiary and setting Lokahi's former holders to own 90% of Glucotrack on an as-converted, fully diluted basis after preferred conversion, with a 10% floor for existing holders. To fund operations and…
Glucotrack appointed Erik Emerson to the Acquiror Board, filling a newly created seat effective upon the Closing.Original SEC Filing: Glucotrack, Inc. [ GCTK ] - 8-K - Jul. 15, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source…
